Global Air Pressure Therapy Market to Reach US$5.9 Billion by 2030

The global market for Air Pressure Therapy estimated at US$4.5 Billion in the year 2024, is expected to reach US$5.9 Billion by 2030, growing at a CAGR of 4.6% over the analysis period 2024-2030. Static Compression Therapy, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$3.5 Billion by the end of the analysis period. Growth in the Dynamic Compression Therapy segment is estimated at 6.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 7.2% CAGR

The Air Pressure Therapy market in the U.S. is estimated at US$1.2 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 7.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.3% and 4.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.

Global Air Pressure Therapy Market – Key Trends & Drivers Summarized

Why Is Air Pressure Therapy Emerging as a Cornerstone in Non-Invasive Treatment Modalities?
Air pressure therapy is witnessing accelerated clinical and commercial adoption as non-invasive treatment solutions gain precedence across healthcare systems worldwide. Leveraging regulated cycles of positive or negative air pressure, these therapies are effectively used for managing conditions such as venous insufficiency, lymphoedema, deep vein thrombosis (DVT) prevention, chronic wounds, and sleep apnea. A significant share of the market is dominated by pneumatic compression devices, which use gradient pressure to improve lymphatic drainage and enhance venous return in patients suffering from circulatory or lymphatic disorders. For hospitals and long-term care facilities, intermittent pneumatic compression (IPC) systems are increasingly being deployed as part of prophylactic DVT protocols for post-operative and immobile patients. Meanwhile, portable compression pumps and wrap-based systems are expanding into home healthcare, driven by an aging population and the global pivot to outpatient and at-home treatment models.

In sleep medicine, continuous positive airway pressure (CPAP) and bi-level positive airway pressure (BiPAP) machines are well-established tools in managing obstructive and central sleep apnea, accounting for a significant portion of air pressure therapy device revenue. The integration of heated humidifiers, auto-adjusting pressure algorithms, and remote monitoring capabilities into CPAP systems has significantly improved therapy adherence and outcomes. Additionally, the expansion of diagnostic services and awareness campaigns by sleep health organizations are identifying a broader spectrum of patients, including those with mild or asymptomatic sleep apnea, who benefit from air pressure therapy. Health insurers across mature markets have begun subsidizing long-term use of PAP machines and related consumables, reinforcing consistent treatment patterns and supporting sustained market demand. These developments are contributing to a growing reliance on air pressure therapy as a non-surgical, low-risk, and outcomes-driven approach across multiple therapeutic areas.

How Are Technology and Customization Reshaping the Patient Experience?
Rapid product innovation and user-centric design upgrades are transforming air pressure therapy devices into smarter, quieter, and more personalized medical solutions. In the sleep apnea segment, the latest CPAP and BiPAP systems feature auto-titrating capabilities that adjust airflow based on real-time respiratory events, thereby eliminating the need for manual pressure calibration and improving patient comfort. Manufacturers are integrating Bluetooth and Wi-Fi modules into these devices, enabling seamless data sharing with physicians via cloud-based platforms and mobile health apps. This connectivity enhances clinical oversight and allows timely therapy adjustments based on compliance trends and breathing anomalies. Furthermore, form factor innovation—including lighter masks, noise-minimizing motors, and ergonomic tubing—is reducing discomfort and stigma associated with long-term device usage, particularly for first-time or pediatric users.

In vascular and lymphatic therapy, technological improvements are yielding portable and wearable pneumatic compression systems that allow patients to continue therapy during regular activity. Smart control panels, pre-programmed treatment modes, and real-time pressure monitoring are enhancing usability, while rechargeable battery integration is improving mobility and adherence in outpatient and home-based settings. Custom-fit garments and multi-chambered inflatable wraps are being developed to accommodate patient-specific anatomies and optimize gradient compression effectiveness. These advancements are helping reduce complications such as ulcer recurrence and lymphedema flare-ups by enabling continuous and convenient prophylaxis. Additionally, artificial intelligence (AI) and machine learning models are beginning to influence next-generation air pressure therapy systems by personalizing treatment protocols based on biometric inputs and historical usage data. This convergence of comfort, intelligence, and adaptability is redefining the therapy experience and increasing its appeal across diverse clinical profiles.

Where Is Demand Growing Across Care Settings and Patient Groups?
The demand for air pressure therapy devices is expanding across acute care hospitals, outpatient clinics, rehabilitation centers, and homecare environments, supported by broader healthcare decentralization trends. In surgical recovery and orthopedics, IPC systems are being routinely integrated into perioperative care pathways to reduce thromboembolic complications and accelerate patient mobilization. Similarly, oncology clinics are increasingly prescribing pneumatic compression for managing secondary lymphedema in breast and pelvic cancer survivors, where early intervention with air pressure therapy improves quality of life and functional mobility. In wound care centers, compression therapy is a first-line modality for treating venous leg ulcers and diabetic foot ulcers, especially when combined with advanced dressings and offloading strategies. The chronic care segment is experiencing heightened demand from the rising prevalence of obesity, cardiovascular disease, and metabolic syndrome, all of which correlate with poor circulation and a higher risk of venous disorders.

Home-based care and remote therapy models are fast becoming the largest growth area within the air pressure therapy landscape. Post-acute patients, elderly individuals, and those with chronic sleep disorders are increasingly managed outside traditional clinical settings, where ease of use, portability, and telemonitoring are essential device attributes. In parallel, the sports medicine and wellness sectors are embracing intermittent air pressure therapy systems for recovery and inflammation reduction, especially in high-performance athletes. This crossover into preventive and lifestyle medicine is opening new consumer-facing sales channels, from physiotherapy chains to e-commerce platforms. Pediatric applications are also gaining visibility, with child-specific CPAP machines and limb compression garments tailored for young patients with sleep-disordered breathing or congenital lymphedema. As healthcare systems pursue value-based models and patients demand convenience without compromising efficacy, air pressure therapy devices are proving indispensable across a broad spectrum of care environments and demographics.

What Factors Are Driving Sustained Growth in the Air Pressure Therapy Market?
The growth in the air pressure therapy market is driven by several factors, including the rising global burden of chronic vascular and respiratory conditions, increased preference for non-invasive therapies, and expanding access to home-based care. One of the primary growth drivers is the increasing diagnosis of obstructive sleep apnea, venous insufficiency, and lymphatic disorders, spurred by heightened awareness, screening programs, and access to specialized clinics. Aging populations in North America, Europe, and parts of Asia are contributing to consistent demand for both CPAP systems and pneumatic compression devices, as older adults face a higher prevalence of comorbidities such as reduced mobility, cardiovascular disease, and poor circulation. Moreover, advances in portable technology and digital health integration are enabling longer treatment adherence and better clinical outcomes in non-hospital environments, further expanding the market’s reach.

Reimbursement support from insurance providers and national health systems is significantly boosting affordability and device adoption, particularly in sleep therapy and post-operative DVT prevention. Meanwhile, manufacturers are diversifying product portfolios to address condition-specific use cases and improve user compliance, from child-friendly CPAPs to gradient-adjustable compression boots. Preventive healthcare initiatives and the growing popularity of wellness-driven recovery therapies in fitness and rehabilitation centers are also reinforcing demand. Lastly, regulatory approvals for newer, AI-enhanced devices and the availability of connected platforms for physician oversight are reinforcing patient and provider confidence in air pressure therapy as a core component of chronic disease management. Together, these trends are shaping a dynamic, multi-dimensional growth path for the global air pressure therapy market across clinical, homecare, and consumer health domains.